Novo Nordisk A/S (NYSE:NVO) Shares Purchased by Nuveen Asset Management LLC

Nuveen Asset Management LLC boosted its holdings in Novo Nordisk A/S (NYSE:NVO - Free Report) by 73.2% during the fourth quarter, according to its most recent Form 13F filing with the SEC. The fund owned 6,244,931 shares of the company's stock after acquiring an additional 2,639,693 shares during the period. Nuveen Asset Management LLC owned 0.14% of Novo Nordisk A/S worth $537,189,000 at the end of the most recent reporting period.

Other large investors have also recently added to or reduced their stakes in the company. Center for Financial Planning Inc. lifted its holdings in Novo Nordisk A/S by 72.4% in the fourth quarter. Center for Financial Planning Inc. now owns 293 shares of the company's stock valued at $25,000 after acquiring an additional 123 shares during the last quarter. Strategic Investment Solutions Inc. IL boosted its position in shares of Novo Nordisk A/S by 2,727.3% during the fourth quarter. Strategic Investment Solutions Inc. IL now owns 311 shares of the company's stock worth $27,000 after buying an additional 300 shares during the period. Transce3nd LLC purchased a new position in shares of Novo Nordisk A/S during the fourth quarter worth $33,000. Kelly Lawrence W & Associates Inc. CA purchased a new position in shares of Novo Nordisk A/S during the fourth quarter worth $39,000. Finally, Albion Financial Group UT boosted its position in shares of Novo Nordisk A/S by 121.4% during the fourth quarter. Albion Financial Group UT now owns 507 shares of the company's stock worth $44,000 after buying an additional 278 shares during the period. 11.54% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

NVO has been the subject of several research analyst reports. BMO Capital Markets restated a "market perform" rating and set a $64.00 price target (down from $105.00) on shares of Novo Nordisk A/S in a research report on Thursday, April 17th. Hsbc Global Res upgraded Novo Nordisk A/S to a "strong-buy" rating in a research note on Monday, April 28th. Morgan Stanley started coverage on Novo Nordisk A/S in a research note on Wednesday, February 12th. They issued an "equal weight" rating on the stock. BNP Paribas started coverage on Novo Nordisk A/S in a research note on Tuesday, April 15th. They issued an "underperform" rating on the stock. Finally, Kepler Capital Markets upgraded Novo Nordisk A/S from a "hold" rating to a "buy" rating in a research note on Thursday, March 13th. Two equities research analysts have rated the stock with a sell rating, five have issued a hold rating, five have issued a buy rating and two have assigned a strong buy rating to the stock. According to data from MarketBeat.com, the company presently has an average rating of "Moderate Buy" and an average target price of $135.00.

Novo Nordisk A/S Stock Performance

NYSE:NVO opened at $64.32 on Thursday. The firm has a market capitalization of $288.64 billion, a PE ratio of 19.55, a price-to-earnings-growth ratio of 0.90 and a beta of 0.65. The business's fifty day moving average price is $67.84 and its 200 day moving average price is $85.23. The company has a debt-to-equity ratio of 0.62, a current ratio of 0.74 and a quick ratio of 0.55. Novo Nordisk A/S has a 12 month low of $57.00 and a 12 month high of $148.15.

Novo Nordisk A/S (NYSE:NVO - Get Free Report) last posted its earnings results on Wednesday, May 7th. The company reported $0.92 EPS for the quarter, meeting the consensus estimate of $0.92. The firm had revenue of $11.87 billion for the quarter. Novo Nordisk A/S had a return on equity of 84.68% and a net margin of 34.81%. On average, sell-side analysts anticipate that Novo Nordisk A/S will post 3.84 earnings per share for the current fiscal year.

Novo Nordisk A/S Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.